Citius Oncology, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 9,353,553 shares, representing 9.99% of Citius Oncology, Inc.'s common stock.
NASDAQ
Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 9,299,917 shares, representing 9.99% of the outstanding common stock of Citius Oncology, Inc.
NASDAQ
Armistice Capital, LLC and Steven Boyd report a 9.79% beneficial ownership stake in Citius Oncology, Inc. common stock.